![\"\"](\"https:\/\/immunebiosolutions.com\/wp-content\/uploads\/2025\/10\/image.png\" "\\"\\"")
<\/figure>\n<\/div>\n\n\nBiolayer Interferometry (BLI)\u00a0<\/h2>\n\n\n\n
Bio-Layer Interferometry (BLI) is an optical technique that monitors biomolecular interactions using disposable biosensor tips. One binding partner, for example, an antibody, is immobilized on the sensor surface, and the tip is then dipped into wells containing the analyte. Binding events alter the interference pattern of reflected light, allowing real-time measurement of association and dissociation\u00a0<\/p>\n\n\n
![\"\"](\"https:\/\/immunebiosolutions.com\/wp-content\/uploads\/2025\/10\/image-1.png\" "\\"\\"")
<\/figure>\n<\/div>\n\n\nAt Immune Biosolutions, we operate both a Carterra LSA (HT-SPR) and a Sartorius Octet RED384, each optimized for specific applications. Typically, for our experiment designs, the Carterra LSA offers higher throughput with better technical replicability than the Octet RED384. This stems from the fact that antibodies are bound to the chip and are exposed to the same ligand solution across all positions. BLI is typically better for very large or very small molecules. Here are a few examples of particular use cases with each instrument\u2019s strengths and limitations.\u00a0<\/p>\n\n\n\n
Rapid Screening of scFvs from Crude Extracts<\/strong>\u00a0<\/h3>\n\n\n\nIn our laboratory, either instrument have optimized procedures to generate high quality data, that\u00a0slightly differ.<\/p>\n\n\n\n
SPR<\/strong><\/h4>\n\n\n\nThe continuous flow system of SPR produces higher-resolution kinetic curves, especially important when accurate rate constants are needed. The best precision is obtained when using purified samples. Therefore, in practice, crude extracts are ideal for rapid pre-screening, with promising candidates later purified and re-analyzed for more detailed kinetic characterization.<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nThe dip-and-read format of BLI makes it well suited for unpurified samples, since there are no microfluidics that might clog. This enables straightforward screening directly from bacterial supernatants. For lower throughput, or for very small or very large molecules, BLI may be well suited.<\/p>\n\n\n\n
Testing Small Molecules binding<\/strong><\/h2>\n\n\n\nSmall molecules generate only subtle refractive index changes, so sensitivity is critical.<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nThe Carterra LSA instrument is less suitable for small molecules. The experimental plan should be discussed specifically according to the client\u2019s molecule type and size. When appropriate, the continuous flow design and high optical sensitivity make it well suited for detecting weak, transient signals.\u00a0<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nSmall molecules are assessed using our BLI platform, for which we have optimized protocols to accurately capture data at these sizes. BLI enables the detection of weak signals that are characteristic of these assays. The experimental design will be discussed in detail according to the specific size and nature of the molecule of interest.<\/p>\n\n\n\n
Screening for Binders to a Large Protein Complex<\/strong><\/h3>\n\n\n\nWhen working with very large protein assemblies, assay format and surface tolerance become critical. Large complexes can present challenges for fluidics-based systems, both in terms of stability and potential clogging.<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nWhile SPR instruments can measure interactions with large complexes, the flow-based design of our Carterra LSA can complicate experiments with such bulky analytes. For this reason, depending on the size, BLI may be more appropriate.\u00a0<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nThe dip-and-read format of BLI makes it especially forgiving for large molecular species. Because there are no microfluidics, issues like clogging or shear stress on the complex are avoided. This makes BLI the preferred platform for screening binders against large protein complexes, where robustness and assay simplicity are more important than ultra-fine kinetic resolution.<\/p>\n\n\n\n
Epitope Binning<\/strong><\/h3>\n\n\n\nEpitope binning is essential for grouping antibodies that recognize overlapping or distinct regions on the same antigen.\u00a0<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nHigh-resolution binning can be performed on SPR, often with greater sensitivity and higher-resolution kinetics curves. It provides a more detailed picture of binding overlaps and competition. \u00a0<\/p>\n\n\n\n
BLI<\/strong>\u00a0<\/h4>\n\n\n\nBLI is well suited for parallel binning experiments with very large molecules. In our setup, we can run up to 16 binning assays simultaneously, which makes it efficient for clustering large antibodies. The trade-off is that the resolution is somewhat lower compared to SPR, meaning closely overlapping epitopes may not be fully distinguished. \u00a0<\/p>\n\n\n\n
In conclusion, both BLI and SPR offer powerful, complementary attributes to advance molecular discovery. Combined, these technologies empower researchers to explore biomolecular interactions from early screening to high-resolution characterization. It ensures a comprehensive, efficient, and reliable approach to accelerate biologics discovery. <\/p>\n\n\n\n
For more details on antibody and biomanufacturing services available at Immune Biosolutions, visit our website<\/a> or contact our team<\/a> directly for more details.<\/p>\n\n\n\nAbout Immune Biosolutions<\/em><\/strong>\u00a0<\/h4>\n\n\n\nImmune Biosolutions<\/em> is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development.\u00a0\u00a0 \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"At Immune Biosolutions, we leverage two core technologies, Bio-Layer Interferometry (BLI) and High-Throughput Surface Plasmon Resonance (HT-SPR), for antibody discovery….<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[55],"tags":[],"class_list":["post-3860","post","type-post","status-publish","format-standard","hentry","category-article"],"acf":[],"taxonomy_info":{"category":[{"value":55,"label":"Article"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":55,"name":"Article","slug":"article","term_group":0,"term_taxonomy_id":55,"taxonomy":"category","description":"","parent":0,"count":2,"filter":"raw","cat_ID":55,"category_count":2,"category_description":"","cat_name":"Article","category_nicename":"article","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=3860"}],"version-history":[{"count":3,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions"}],"predecessor-version":[{"id":3869,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions\/3869"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=3860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=3860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=3860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
The continuous flow system of SPR produces higher-resolution kinetic curves, especially important when accurate rate constants are needed. The best precision is obtained when using purified samples. Therefore, in practice, crude extracts are ideal for rapid pre-screening, with promising candidates later purified and re-analyzed for more detailed kinetic characterization.<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nThe dip-and-read format of BLI makes it well suited for unpurified samples, since there are no microfluidics that might clog. This enables straightforward screening directly from bacterial supernatants. For lower throughput, or for very small or very large molecules, BLI may be well suited.<\/p>\n\n\n\n
Testing Small Molecules binding<\/strong><\/h2>\n\n\n\nSmall molecules generate only subtle refractive index changes, so sensitivity is critical.<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nThe Carterra LSA instrument is less suitable for small molecules. The experimental plan should be discussed specifically according to the client\u2019s molecule type and size. When appropriate, the continuous flow design and high optical sensitivity make it well suited for detecting weak, transient signals.\u00a0<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nSmall molecules are assessed using our BLI platform, for which we have optimized protocols to accurately capture data at these sizes. BLI enables the detection of weak signals that are characteristic of these assays. The experimental design will be discussed in detail according to the specific size and nature of the molecule of interest.<\/p>\n\n\n\n
Screening for Binders to a Large Protein Complex<\/strong><\/h3>\n\n\n\nWhen working with very large protein assemblies, assay format and surface tolerance become critical. Large complexes can present challenges for fluidics-based systems, both in terms of stability and potential clogging.<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nWhile SPR instruments can measure interactions with large complexes, the flow-based design of our Carterra LSA can complicate experiments with such bulky analytes. For this reason, depending on the size, BLI may be more appropriate.\u00a0<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nThe dip-and-read format of BLI makes it especially forgiving for large molecular species. Because there are no microfluidics, issues like clogging or shear stress on the complex are avoided. This makes BLI the preferred platform for screening binders against large protein complexes, where robustness and assay simplicity are more important than ultra-fine kinetic resolution.<\/p>\n\n\n\n
Epitope Binning<\/strong><\/h3>\n\n\n\nEpitope binning is essential for grouping antibodies that recognize overlapping or distinct regions on the same antigen.\u00a0<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nHigh-resolution binning can be performed on SPR, often with greater sensitivity and higher-resolution kinetics curves. It provides a more detailed picture of binding overlaps and competition. \u00a0<\/p>\n\n\n\n
BLI<\/strong>\u00a0<\/h4>\n\n\n\nBLI is well suited for parallel binning experiments with very large molecules. In our setup, we can run up to 16 binning assays simultaneously, which makes it efficient for clustering large antibodies. The trade-off is that the resolution is somewhat lower compared to SPR, meaning closely overlapping epitopes may not be fully distinguished. \u00a0<\/p>\n\n\n\n
In conclusion, both BLI and SPR offer powerful, complementary attributes to advance molecular discovery. Combined, these technologies empower researchers to explore biomolecular interactions from early screening to high-resolution characterization. It ensures a comprehensive, efficient, and reliable approach to accelerate biologics discovery. <\/p>\n\n\n\n
For more details on antibody and biomanufacturing services available at Immune Biosolutions, visit our website<\/a> or contact our team<\/a> directly for more details.<\/p>\n\n\n\nAbout Immune Biosolutions<\/em><\/strong>\u00a0<\/h4>\n\n\n\nImmune Biosolutions<\/em> is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development.\u00a0\u00a0 \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"At Immune Biosolutions, we leverage two core technologies, Bio-Layer Interferometry (BLI) and High-Throughput Surface Plasmon Resonance (HT-SPR), for antibody discovery….<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[55],"tags":[],"class_list":["post-3860","post","type-post","status-publish","format-standard","hentry","category-article"],"acf":[],"taxonomy_info":{"category":[{"value":55,"label":"Article"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":55,"name":"Article","slug":"article","term_group":0,"term_taxonomy_id":55,"taxonomy":"category","description":"","parent":0,"count":2,"filter":"raw","cat_ID":55,"category_count":2,"category_description":"","cat_name":"Article","category_nicename":"article","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=3860"}],"version-history":[{"count":3,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions"}],"predecessor-version":[{"id":3869,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions\/3869"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=3860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=3860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=3860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Small molecules generate only subtle refractive index changes, so sensitivity is critical.<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nThe Carterra LSA instrument is less suitable for small molecules. The experimental plan should be discussed specifically according to the client\u2019s molecule type and size. When appropriate, the continuous flow design and high optical sensitivity make it well suited for detecting weak, transient signals.\u00a0<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nSmall molecules are assessed using our BLI platform, for which we have optimized protocols to accurately capture data at these sizes. BLI enables the detection of weak signals that are characteristic of these assays. The experimental design will be discussed in detail according to the specific size and nature of the molecule of interest.<\/p>\n\n\n\n
Screening for Binders to a Large Protein Complex<\/strong><\/h3>\n\n\n\nWhen working with very large protein assemblies, assay format and surface tolerance become critical. Large complexes can present challenges for fluidics-based systems, both in terms of stability and potential clogging.<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nWhile SPR instruments can measure interactions with large complexes, the flow-based design of our Carterra LSA can complicate experiments with such bulky analytes. For this reason, depending on the size, BLI may be more appropriate.\u00a0<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nThe dip-and-read format of BLI makes it especially forgiving for large molecular species. Because there are no microfluidics, issues like clogging or shear stress on the complex are avoided. This makes BLI the preferred platform for screening binders against large protein complexes, where robustness and assay simplicity are more important than ultra-fine kinetic resolution.<\/p>\n\n\n\n
Epitope Binning<\/strong><\/h3>\n\n\n\nEpitope binning is essential for grouping antibodies that recognize overlapping or distinct regions on the same antigen.\u00a0<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nHigh-resolution binning can be performed on SPR, often with greater sensitivity and higher-resolution kinetics curves. It provides a more detailed picture of binding overlaps and competition. \u00a0<\/p>\n\n\n\n
BLI<\/strong>\u00a0<\/h4>\n\n\n\nBLI is well suited for parallel binning experiments with very large molecules. In our setup, we can run up to 16 binning assays simultaneously, which makes it efficient for clustering large antibodies. The trade-off is that the resolution is somewhat lower compared to SPR, meaning closely overlapping epitopes may not be fully distinguished. \u00a0<\/p>\n\n\n\n
In conclusion, both BLI and SPR offer powerful, complementary attributes to advance molecular discovery. Combined, these technologies empower researchers to explore biomolecular interactions from early screening to high-resolution characterization. It ensures a comprehensive, efficient, and reliable approach to accelerate biologics discovery. <\/p>\n\n\n\n
For more details on antibody and biomanufacturing services available at Immune Biosolutions, visit our website<\/a> or contact our team<\/a> directly for more details.<\/p>\n\n\n\nAbout Immune Biosolutions<\/em><\/strong>\u00a0<\/h4>\n\n\n\nImmune Biosolutions<\/em> is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development.\u00a0\u00a0 \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"At Immune Biosolutions, we leverage two core technologies, Bio-Layer Interferometry (BLI) and High-Throughput Surface Plasmon Resonance (HT-SPR), for antibody discovery….<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[55],"tags":[],"class_list":["post-3860","post","type-post","status-publish","format-standard","hentry","category-article"],"acf":[],"taxonomy_info":{"category":[{"value":55,"label":"Article"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":55,"name":"Article","slug":"article","term_group":0,"term_taxonomy_id":55,"taxonomy":"category","description":"","parent":0,"count":2,"filter":"raw","cat_ID":55,"category_count":2,"category_description":"","cat_name":"Article","category_nicename":"article","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=3860"}],"version-history":[{"count":3,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions"}],"predecessor-version":[{"id":3869,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions\/3869"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=3860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=3860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=3860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Small molecules are assessed using our BLI platform, for which we have optimized protocols to accurately capture data at these sizes. BLI enables the detection of weak signals that are characteristic of these assays. The experimental design will be discussed in detail according to the specific size and nature of the molecule of interest.<\/p>\n\n\n\n
Screening for Binders to a Large Protein Complex<\/strong><\/h3>\n\n\n\nWhen working with very large protein assemblies, assay format and surface tolerance become critical. Large complexes can present challenges for fluidics-based systems, both in terms of stability and potential clogging.<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nWhile SPR instruments can measure interactions with large complexes, the flow-based design of our Carterra LSA can complicate experiments with such bulky analytes. For this reason, depending on the size, BLI may be more appropriate.\u00a0<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nThe dip-and-read format of BLI makes it especially forgiving for large molecular species. Because there are no microfluidics, issues like clogging or shear stress on the complex are avoided. This makes BLI the preferred platform for screening binders against large protein complexes, where robustness and assay simplicity are more important than ultra-fine kinetic resolution.<\/p>\n\n\n\n
Epitope Binning<\/strong><\/h3>\n\n\n\nEpitope binning is essential for grouping antibodies that recognize overlapping or distinct regions on the same antigen.\u00a0<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nHigh-resolution binning can be performed on SPR, often with greater sensitivity and higher-resolution kinetics curves. It provides a more detailed picture of binding overlaps and competition. \u00a0<\/p>\n\n\n\n
BLI<\/strong>\u00a0<\/h4>\n\n\n\nBLI is well suited for parallel binning experiments with very large molecules. In our setup, we can run up to 16 binning assays simultaneously, which makes it efficient for clustering large antibodies. The trade-off is that the resolution is somewhat lower compared to SPR, meaning closely overlapping epitopes may not be fully distinguished. \u00a0<\/p>\n\n\n\n
In conclusion, both BLI and SPR offer powerful, complementary attributes to advance molecular discovery. Combined, these technologies empower researchers to explore biomolecular interactions from early screening to high-resolution characterization. It ensures a comprehensive, efficient, and reliable approach to accelerate biologics discovery. <\/p>\n\n\n\n
For more details on antibody and biomanufacturing services available at Immune Biosolutions, visit our website<\/a> or contact our team<\/a> directly for more details.<\/p>\n\n\n\nAbout Immune Biosolutions<\/em><\/strong>\u00a0<\/h4>\n\n\n\nImmune Biosolutions<\/em> is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development.\u00a0\u00a0 \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"At Immune Biosolutions, we leverage two core technologies, Bio-Layer Interferometry (BLI) and High-Throughput Surface Plasmon Resonance (HT-SPR), for antibody discovery….<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[55],"tags":[],"class_list":["post-3860","post","type-post","status-publish","format-standard","hentry","category-article"],"acf":[],"taxonomy_info":{"category":[{"value":55,"label":"Article"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":55,"name":"Article","slug":"article","term_group":0,"term_taxonomy_id":55,"taxonomy":"category","description":"","parent":0,"count":2,"filter":"raw","cat_ID":55,"category_count":2,"category_description":"","cat_name":"Article","category_nicename":"article","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=3860"}],"version-history":[{"count":3,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions"}],"predecessor-version":[{"id":3869,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions\/3869"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=3860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=3860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=3860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
While SPR instruments can measure interactions with large complexes, the flow-based design of our Carterra LSA can complicate experiments with such bulky analytes. For this reason, depending on the size, BLI may be more appropriate.\u00a0<\/p>\n\n\n\n
BLI<\/strong><\/h4>\n\n\n\nThe dip-and-read format of BLI makes it especially forgiving for large molecular species. Because there are no microfluidics, issues like clogging or shear stress on the complex are avoided. This makes BLI the preferred platform for screening binders against large protein complexes, where robustness and assay simplicity are more important than ultra-fine kinetic resolution.<\/p>\n\n\n\n
Epitope Binning<\/strong><\/h3>\n\n\n\nEpitope binning is essential for grouping antibodies that recognize overlapping or distinct regions on the same antigen.\u00a0<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nHigh-resolution binning can be performed on SPR, often with greater sensitivity and higher-resolution kinetics curves. It provides a more detailed picture of binding overlaps and competition. \u00a0<\/p>\n\n\n\n
BLI<\/strong>\u00a0<\/h4>\n\n\n\nBLI is well suited for parallel binning experiments with very large molecules. In our setup, we can run up to 16 binning assays simultaneously, which makes it efficient for clustering large antibodies. The trade-off is that the resolution is somewhat lower compared to SPR, meaning closely overlapping epitopes may not be fully distinguished. \u00a0<\/p>\n\n\n\n
In conclusion, both BLI and SPR offer powerful, complementary attributes to advance molecular discovery. Combined, these technologies empower researchers to explore biomolecular interactions from early screening to high-resolution characterization. It ensures a comprehensive, efficient, and reliable approach to accelerate biologics discovery. <\/p>\n\n\n\n
For more details on antibody and biomanufacturing services available at Immune Biosolutions, visit our website<\/a> or contact our team<\/a> directly for more details.<\/p>\n\n\n\nAbout Immune Biosolutions<\/em><\/strong>\u00a0<\/h4>\n\n\n\nImmune Biosolutions<\/em> is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development.\u00a0\u00a0 \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"At Immune Biosolutions, we leverage two core technologies, Bio-Layer Interferometry (BLI) and High-Throughput Surface Plasmon Resonance (HT-SPR), for antibody discovery….<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[55],"tags":[],"class_list":["post-3860","post","type-post","status-publish","format-standard","hentry","category-article"],"acf":[],"taxonomy_info":{"category":[{"value":55,"label":"Article"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":55,"name":"Article","slug":"article","term_group":0,"term_taxonomy_id":55,"taxonomy":"category","description":"","parent":0,"count":2,"filter":"raw","cat_ID":55,"category_count":2,"category_description":"","cat_name":"Article","category_nicename":"article","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=3860"}],"version-history":[{"count":3,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions"}],"predecessor-version":[{"id":3869,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions\/3869"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=3860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=3860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=3860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Epitope binning is essential for grouping antibodies that recognize overlapping or distinct regions on the same antigen.\u00a0<\/p>\n\n\n\n
SPR<\/strong>\u00a0<\/h4>\n\n\n\nHigh-resolution binning can be performed on SPR, often with greater sensitivity and higher-resolution kinetics curves. It provides a more detailed picture of binding overlaps and competition. \u00a0<\/p>\n\n\n\n
BLI<\/strong>\u00a0<\/h4>\n\n\n\nBLI is well suited for parallel binning experiments with very large molecules. In our setup, we can run up to 16 binning assays simultaneously, which makes it efficient for clustering large antibodies. The trade-off is that the resolution is somewhat lower compared to SPR, meaning closely overlapping epitopes may not be fully distinguished. \u00a0<\/p>\n\n\n\n
In conclusion, both BLI and SPR offer powerful, complementary attributes to advance molecular discovery. Combined, these technologies empower researchers to explore biomolecular interactions from early screening to high-resolution characterization. It ensures a comprehensive, efficient, and reliable approach to accelerate biologics discovery. <\/p>\n\n\n\n
For more details on antibody and biomanufacturing services available at Immune Biosolutions, visit our website<\/a> or contact our team<\/a> directly for more details.<\/p>\n\n\n\nAbout Immune Biosolutions<\/em><\/strong>\u00a0<\/h4>\n\n\n\nImmune Biosolutions<\/em> is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development.\u00a0\u00a0 \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"At Immune Biosolutions, we leverage two core technologies, Bio-Layer Interferometry (BLI) and High-Throughput Surface Plasmon Resonance (HT-SPR), for antibody discovery….<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[55],"tags":[],"class_list":["post-3860","post","type-post","status-publish","format-standard","hentry","category-article"],"acf":[],"taxonomy_info":{"category":[{"value":55,"label":"Article"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":55,"name":"Article","slug":"article","term_group":0,"term_taxonomy_id":55,"taxonomy":"category","description":"","parent":0,"count":2,"filter":"raw","cat_ID":55,"category_count":2,"category_description":"","cat_name":"Article","category_nicename":"article","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=3860"}],"version-history":[{"count":3,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions"}],"predecessor-version":[{"id":3869,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions\/3869"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=3860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=3860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=3860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
BLI is well suited for parallel binning experiments with very large molecules. In our setup, we can run up to 16 binning assays simultaneously, which makes it efficient for clustering large antibodies. The trade-off is that the resolution is somewhat lower compared to SPR, meaning closely overlapping epitopes may not be fully distinguished. \u00a0<\/p>\n\n\n\n
In conclusion, both BLI and SPR offer powerful, complementary attributes to advance molecular discovery. Combined, these technologies empower researchers to explore biomolecular interactions from early screening to high-resolution characterization. It ensures a comprehensive, efficient, and reliable approach to accelerate biologics discovery. <\/p>\n\n\n\n
For more details on antibody and biomanufacturing services available at Immune Biosolutions, visit our website<\/a> or contact our team<\/a> directly for more details.<\/p>\n\n\n\n Immune Biosolutions<\/em> is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development.\u00a0\u00a0 \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":" At Immune Biosolutions, we leverage two core technologies, Bio-Layer Interferometry (BLI) and High-Throughput Surface Plasmon Resonance (HT-SPR), for antibody discovery….<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[55],"tags":[],"class_list":["post-3860","post","type-post","status-publish","format-standard","hentry","category-article"],"acf":[],"taxonomy_info":{"category":[{"value":55,"label":"Article"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":55,"name":"Article","slug":"article","term_group":0,"term_taxonomy_id":55,"taxonomy":"category","description":"","parent":0,"count":2,"filter":"raw","cat_ID":55,"category_count":2,"category_description":"","cat_name":"Article","category_nicename":"article","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=3860"}],"version-history":[{"count":3,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions"}],"predecessor-version":[{"id":3869,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/3860\/revisions\/3869"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=3860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=3860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=3860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}About Immune Biosolutions<\/em><\/strong>\u00a0<\/h4>\n\n\n\n